Roscovitine

CAS: 186692-46-6

Ref. TR-R684000

Información del producto

• Nombre: Roscovitine
• Sinónimos: (2R)-2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol, (R)-2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol, 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine, CYC 202, (R)-Roscovitine, R-Roscovitine, Roscovitin, Seliciclib, (2R)-2-[[6-(Benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol, (2R)-2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol, (2R)-2-{[6-(benzylamino)-9-(propan-2-yl)-9H-purin-2-yl]amino}butan-1-ol, 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (2R)-, 1-Butanol, 2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-, (R)-, Cyc 202, Cyc202, Nsc 701554, Unii-0Es1C2Kq94

Descripción

Applications Roscovitine is a potent and selective inhibitor of cyclin-dependent kinases (CDKs). Roscovitine has been found to produce apoptosis in treated cancerous cells of non-small cell lung cancer (NSCLC) and other cancers. Studies show that Roscovitine displays increased anti-mitotic activity at the G1/S and G2/M phases of the cell cycle. Roscovitine maybe useful in the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation disorders.
References De Azevedo, W.F. et al.: Eur. J. Biochem., 43, 518 (1997); Planchais, S. et al.: Plant J., 12, 191 (1997); Mgbonyebi O.P. et al.: Anticancer Res., 18, 751 (1998); MacCallum, D.E. et al.: Cancer Res., 65, 5399 (2005);

• Marca: TRC

Propiedades químicas

• Peso molecular: 354.4493
• Fórmula: C₁₉H₂₆N₆O
• Color/Forma: Off White Solid
• InChI: InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1
• Clave InChI: InChIKey=BTIHMVBBUGXLCJ-OAHLLOKOSA-N
• SMILES: CC[C@H](CO)N=c1nc2c(ncn2C(C)C)c(NCc2ccccc2)[nH]1